| Ytd | -97.98% | |
| 1y | -99.23% |
| Open | 0.02 | Prev Close | 0.01 | Low | 0.01 | High | 0.02 | Mkt Cap | 58.61M |
| Vol | 3.06M | Avg Vol | 347.79K | EPS | -1.29 | P/E | N/A | Forward P/E | -0.76 |
| Beta | 0.42 | Short Ratio | 1.89 | Inst. Own | 76.79% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-14 | 50-d Avg | 0.99 | 200-d Avg | 1.26 | 1yr Est | 9.00 |
IOBT News
IO Biotech, Inc. (NASDAQ: IOBT - Get Free Report) has received an average rating of "Reduce" from th
Applied Optoelectronics Inc (NASDAQ: AAOI) rose in pre-market trading after securing an 800G transce
Major M&A deals this week include: Eli Lilly's $7.8 billion purchase of Centessa Pharmaceuti
US stocks rise on Tuesday, with NASDAQ up 2% and Dow up 1.37%. Communication services shares gain 2.
IO Biotech, Inc. (NASDAQ: IOBT - Get Free Report) has received a consensus rating of "Reduce" from t
IO Biotech, Inc. (NASDAQ: IOBT - Get Free Report) was the target of a significant drop in short inte
IO Biotech, Inc. (IOBT) witnesses a hammer chart pattern, indicating support found by the stock afte
IO Biotech, Inc. (NASDAQ: IOBT - Get Free Report) was the target of a significant increase in short
Raymond James engaged as financial advisor Reduction in force implemented NEW YORK, Jan. 30, 2026 (G
NEW YORK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceu
Findings provide scientific insights into the contributions of IDO1 and PD-L1 vaccination to PD-1 bl
NEW YORK, Nov. 26, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceu
IO Biotech, Inc. (IOBT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism abou
IO Biotech, Inc. (NASDAQ: IOBT - Get Free Report) has earned an average rating of "Hold" from the si
Topline data from Phase 3 (IOB-013) clinical trial in advanced melanoma presented at ESMO; data high
NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceu
Pre-clinical data for IO Biotech's next T-win vaccine candidate, IO112 targeting arginase 1, demonst
Cylembio plus pembrolizumab achieved a clinically relevant 19.4 months median progression free survi
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining around 150 points on Monda
FDA recommends that IO Biotech not submit a Biologics License Application (BLA) based on the data fr
Oral presentation will highlight the results from the randomized Phase 3 trial (IOB-013/KN-D18) of I
IO Biotech, Inc. (NASDAQ:IOBT ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9,
NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmace
IO Biotech, Inc. (IOBT) might move higher on growing optimism about its earnings prospects, which is